Close menu




October 28th, 2021 | 12:04 CEST

Canopy, Tilray, Sativa Wellness, Formycon - Finding the next cannabis rocket!

  • Cannabis
Photo credits: pixabay.com

The big bull market in cannabis ran through 2018 and 2019, and then in 2020, the reality set in that only a fraction of states around the world will implement general licensing for hemp. The newly elected federal parliament has its first constituent session these days. Climate change and investments in digital infrastructure are two of the most important topics in the coalition negotiations to form a new federal government. One topic that is not quite so high on the list of priorities, but is already causing a lot of excitement in the run-up, is the possible legalization of cannabis. The Greens and FDP have been advocating legal, regulated trade for some time. Of course, nothing has been decided yet, but the outgoing federal government's drug commissioner, Daniela Ludwig of the CSU, already warns of the consequences. We take a look at important industry representatives.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: CANOPY GROWTH | CA1380351009 , TILRAY INC. CL.2 DL-_0001 | US88688T1007 , SATIVA WELLNESS GROUP INC | CA80403E1043 , FORMYCON AG | DE000A1EWVY8

Table of contents:


    Canopy versus Tilray - Who will win the race?

    The public discussions in Germany on the (partial) legalization of cannabis products have been met with approval throughout the industry. The key point: Germany has a lot of weight within the European legislature in Brussels - some believe in faster legalization legislative processes or a significant acceleration of the topic if Germany steps on the gas here.

    The German pharmaceutical industry is sitting up and taking notice because they would not be in the right position if it were to happen quickly. Should cannabis be fully legalized and sold in regular stores? While this question is heating tempers in Germany, other countries are already further ahead. For example, in Canada, where cannabis was already released three years ago. Meanwhile, the excitement of the early days has subsided, and the consequences can be assessed quite well. There are already many positive examples that show promising results for medical purposes, especially in the therapy of depression diseases and other mental disorders.

    The major Canadian cannabis stocks such as Canopy, Tilray or Aurora are in urgent need of a revival from an investor's point of view, as their shares have been going sideways for 12 months and are between 40% and 70% away from their highs. Only the merger between Tilray and Aphria brought back some momentum. With the possible political turnaround in Germany, Canopy Growth, Tilray and Aurora Cannabis could benefit somewhat. However, the regulatory starting signal has not yet been given, so it is advisable to remain on the sidelines for the time being.

    Sativa Wellness Group - A new player in the healthcare market

    Albeit a major bone of contention, cannabis has gained its place in areas of healing therapy. Especially with the advent of the COVID-19 pandemic, medicine, in general, is facing the challenge of admitting new ways of thinking and including alternative healing methods in the discussion.

    The Sativa Wellness Group is a British provider of various services related to cannabis. From self-therapy to wellness, the focus is on cannabidiol (CBD), laboratory services related to the active ingredients from the hemp plant, and other wellness products. The female cannabis plant contains at least 750 chemicals and 100 other-acting cannabinoids, which historically have already shown their effectiveness in many indications. The global market has already established itself and is growing at over 20% annually.

    Like other players in the market, Sativa Wellness naturally hopes for the complete legalization of its products. Currently, the Company is already well on its way with its strategic positioning. The already established trading company, Goodbody Botanicals, has made profits throughout 2021 to date after losses in previous years. Since the last quarter, the entire group has been generating positive cash flow and currently has a healthy cash position to support the formulated acquisition strategy.

    Digitalization in the healthcare sector is also taking hold at Sativa. Recently, the wellness division announced its intention to enter the market with telemedical consulting services. That hits the nail on the head because, during the pandemic, people in Germany learned to prioritize the topic of health more strongly as part of their life planning. The chances are, therefore, quite good for Sativa. The Sativa Wellness share is listed in Canada under SWEL as well as in Germany. With the current successes and the new COVID-19 blood tests, the market capitalization of CAD 20 million is not too high. An initial position in the fast-growing Company makes sense.

    Formycon - There is news on FBY207

    The Munich-based biotech Company is putting its research entirely at the service of people's health. In July, the Company had reported government funding in connection with the promising COVID-19 drug FYB207. The drug is said to completely block cell infection in the human body by the SARS-CoV-2 virus.

    Currently, Formycon already reports a license and cooperation agreement with SCG Cell Therapy. It involves the development and marketing of FYB207. Singapore-based SCG will receive an exclusive license from Formycon to develop, manufacture and market FYB207 in the Asia-Pacific region. Japan is excluded; this Asian submarket will remain with Formycon. In addition, SCG will gain access to Formycon's ACE2 fusion protein technology. Within the deal, Formycon is eligible for milestone payments of up to EUR 63.5 million. In addition, royalties on sales will be in the low double-digit percentage range.

    In our eyes, this is again good news from Martinsried. Nevertheless, the Formycon share has been somewhat quiet in recent weeks. The EUR 55 mark should be watched closely; a breakout to the upside would be a starting signal for a new rally.


    The cannabis industry is now slowly entering its teenage years. The initial problems have been cleared, and the protagonists of the industry know their strengths and weaknesses. Canopy, Tilray and Aurora are well-known standard stocks. Sativa Wellness Group is a therapy and testing company with excellent positioning.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read

    Commented by Fabian Lorenz on December 1st, 2022 | 11:55 CET

    Comeback stocks: Nel, Aurora Cannabis, Barrick Gold, Tocvan Ventures

    • Mining
    • Gold
    • Hydrogen
    • Cannabis

    Gold, cannabis and hydrogen could be among the top trends of the coming year - also on the stock market. Due to full order books, Nel could be poised for a comeback in 2023. At least sales are already secured until mid-2024. Now, all that is left is to cut the loss to reach analysts' price targets. Aurora Cannabis has largely completed its turnaround and is also hoping for legalization in Europe and the US. Driven by a strong gold price, mining stocks have already jumped. Now exploration companies should follow. Tocvan Ventures is one of them. And with the gold explorer, investors can look forward to a regular news flow in the coming year. Are the three candidates comeback stocks in 2023?

    Read

    Commented by Stefan Feulner on November 28th, 2022 | 10:41 CET

    SynBiotic SE, Cardiol Therapeutics, Canopy Growth - Like hitting the jackpot

    • Cannabis
    • Investments

    The final draft of the German government's key issues paper on the legalization of cannabis in Germany is ready, and final approval is likely to be a mere formality. For the companies concerned, this is equivalent to winning the lottery. The global cannabis market is expected to grow by 13.9% annually to USD 64.91 billion between 2022 and 2027. However, these profit increases have yet to reach the stock market. Some companies, for example, are trading below cash, while others lost more than 90% of their value in the correction that has been underway since 2019.

    Read